OptimizeRx Stockholders Approve Key Governance Proposals

OptimizeRx ( (OPRX) ) has provided an update.

OptimizeRx held its 2025 Annual Meeting of Stockholders on June 11, 2025, where stockholders voted on three key proposals. The proposals included the election of five directors, approval of executive compensation, and ratification of UHY LLP as the independent accounting firm. All proposals were approved, impacting the company’s governance and financial oversight for the 2025 fiscal year.

The most recent analyst rating on (OPRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.

Spark’s Take on OPRX Stock

According to Spark, TipRanks’ AI Analyst, OPRX is a Outperform.

OptimizeRx’s strong revenue growth and strategic enhancements, particularly the transition to a subscription model, are significant positives. Technical indicators show bullish momentum, supporting a positive outlook. However, profitability challenges and valuation concerns moderate the overall score.

To see Spark’s full report on OPRX stock, click here.

More about OptimizeRx

Average Trading Volume: 317,300

Technical Sentiment Signal: Hold

Current Market Cap: $263.9M

For detailed information about OPRX stock, go to TipRanks’ Stock Analysis page.